Verona Pharma (VRNA) Price & Analysis

Compare

868 Followers

VRNA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$22.50 - $105.50

Previous CloseN/A

Volume658.49K

Average Volume (3M)5.80M

Market Cap

$9.05B

Enterprise Value$8.40B

Total Cash (Recent Filing)$401.42M

Total Debt (Recent Filing)$2.13M

Price to Earnings (P/E)―

Beta1.63

Next Earnings

Nov 11, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.13

Shares Outstanding86,192,120

10 Day Avg. Volume2,042,367

30 Day Avg. Volume5,798,829

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.93

Enterprise Value/Revenue70.90

Enterprise Value/Gross Profit74.85

Enterprise Value/Ebitda-47.73

Forecast

1Y Price Target

$106.22

Price Target Upside0.98% Upside

Rating ConsensusHold

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Drug ApprovalOhtuvayre, approved as a first-in-class PDE3 and PDE4 dual inhibitor, shows strong revenue growth since its launch.

Market AdoptionOhtuvayre has quickly gained traction among physicians and patients, indicating strong market adoption in the COPD space.

Strategic AcquisitionMerck's acquisition of Verona Pharma for $107 per ADS is valued for its multibillion-dollar potential in cardiopulmonary disease treatments.

Bears Say

Competition And Market PositionDespite inclusion in the GOLD treatment guidelines for COPD, Ohtuvayre is only briefly mentioned with weak language, suggesting competitive challenges.

Downgrade In RatingThe stock rating was downgraded to Neutral from Buy following the deal announcement.

Financial ImpactIncreased costs have been modeled, resulting in a reduction in net income for 2025.

Verona Pharma News

Verona Pharma downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

1M ago

VRNA

Verona Pharma downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler downgraded Verona Pharma (VRNA) to Neutral from Overweight with a price target of $107, down from...

1M ago

VRNA

Verona Pharma downgraded to Hold from Buy at Truist

Truist downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100,...

1M ago

MRK

VRNA

Verona Pharma downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK)...

1M ago

VRNA

Verona Pharma downgraded to Neutral from Buy at Roth Capital

Roth Capital analyst Boobalan Pachaiyappan downgraded Verona Pharma (VRNA) to Neutral from Buy with a price target of...

1M ago

VRNA

Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal

Verona Pharma stock soared on Wednesday after the Ohtuvayre maker announced a $10 billion deal with Merck. ...

1M ago

MRK

VRNA

Verona Pharma downgraded to Neutral from Buy at BTIG

BTIG downgraded Verona Pharma (VRNA) to Neutral from Buy without a price target after Merck (MRK) announced it...

1M ago

VRNA

Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo

Wells Fargo downgraded Verona Pharma (VRNA) to Equal Weight from Overweight with a price target of $107, down...

1M ago

MRK

VRNA

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Investors will find plenty of stock market stories to read today with the TipRanks daily wrap-up. ...

1M ago

AMD

MRK

Verona Pharma downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from...

1M ago

MRK

VRNA

Merck’s Acquisition of Verona Pharma Caps Stock’s Upside Potential, Downgraded to Hold

Verona Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tara Bancroft from...

1M ago

VRNA

Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz

The major averages were mostly higher near noon, driven by cautious optimism following an overnight lull in volatility....

1M ago

EXK

Verona Pharma downgraded to Hold from Buy at Canaccord

Canaccord downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $106,...

1M ago

VRNA

Verona Pharma Acquired by Merck for $10 Billion

Verona Pharma ( ($VRNA) ) has provided an announcement. On July 8, 2025, Verona Pharma entered into a...

1M ago

VRNA

VRNA FAQ

What was Verona Pharma Plc’s price range in the past 12 months?

Verona Pharma Plc lowest stock price was $22.50 and its highest was $105.50 in the past 12 months.

What is Verona Pharma Plc’s market cap?

Verona Pharma Plc’s market cap is $9.05B.

When is Verona Pharma Plc’s upcoming earnings report date?

Verona Pharma Plc’s upcoming earnings report date is Nov 11, 2025 which is in 90 days.

How were Verona Pharma Plc’s earnings last quarter?

Verona Pharma Plc released its earnings results on Jul 31, 2025. The company reported $0.133 earnings per share for the quarter, beating the consensus estimate of $0.057 by $0.076.

Is Verona Pharma Plc overvalued?

According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Verona Pharma Plc pay dividends?

Verona Pharma Plc does not currently pay dividends.

What is Verona Pharma Plc’s EPS estimate?

Verona Pharma Plc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Verona Pharma Plc have?

Verona Pharma Plc has 86,192,120 shares outstanding.

What happened to Verona Pharma Plc’s price movement after its last earnings report?

Verona Pharma Plc reported an EPS of $0.133 in its last earnings report, beating expectations of $0.057. Following the earnings report the stock price went down -0.048%.

Which hedge fund is a major shareholder of Verona Pharma Plc?

Currently, no hedge funds are holding shares in VRNA

Verona Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.38%

Trailing 12-Months

Asset Growth

31.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Verona Pharma Plc

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma (VRNA) Earnings & Revenues

Historic Earnings Reports

VRNA Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call for Verona Pharma plc reflected a positive sentiment overall, driven by the successful launch and strong sales of O2VERE, significant financial achievements, and robust progress in global regulatory and intellectual property strategies. Despite some financial losses and high expenses, the company's strong cash position and strategic financing provide a solid foundation for continued growth.View all VRNA earnings summaries

VRNA Stock 12 Month Forecast

Average Price Target

$106.22

▲(0.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","61":"$61","108":"$108","37.5":"$37.5","84.5":"$84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$107.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":106.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$106.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,37.5,61,84.5,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.75076923076924,93.02153846153847,94.2923076923077,95.56307692307692,96.83384615384615,98.10461538461539,99.37538461538462,100.64615384615385,101.91692307692308,103.18769230769232,104.45846153846153,105.72923076923077,{"y":107,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.69076923076923,92.90153846153846,94.1123076923077,95.32307692307693,96.53384615384616,97.74461538461539,98.95538461538462,100.16615384615385,101.37692307692308,102.58769230769231,103.79846153846154,105.00923076923077,{"y":106.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,90.48,91.21230769230769,91.94461538461539,92.67692307692307,93.40923076923077,94.14153846153846,94.87384615384616,95.60615384615384,96.33846153846154,97.07076923076923,97.80307692307693,98.53538461538461,99.2676923076923,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.99,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.63,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.48,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >